Alexion Pharmaceuticals, Inc. (ALXN) Given Average Rating of “Buy” by Analysts
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been given a consensus recommendation of “Buy” by the twenty-eight ratings firms that are covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $157.21.
Several research analysts have recently weighed in on the stock. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, July 14th. UBS AG restated a “buy” rating and issued a $142.00 target price (up previously from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, June 9th. Credit Suisse Group set a $164.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th.
In other news, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the transaction, the executive vice president now owns 26,704 shares in the company, valued at $3,738,560. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,070 shares of company stock valued at $2,416,869. 4.35% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of ALXN. BlackRock Inc. boosted its stake in Alexion Pharmaceuticals by 7.0% during the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after buying an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. grew its holdings in Alexion Pharmaceuticals by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after buying an additional 318,375 shares in the last quarter. State Street Corp grew its holdings in Alexion Pharmaceuticals by 5.0% during the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after buying an additional 561,962 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Alexion Pharmaceuticals by 0.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock valued at $751,363,000 after buying an additional 25,724 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Alexion Pharmaceuticals by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after acquiring an additional 64,800 shares during the last quarter. Institutional investors own 94.17% of the company’s stock.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.41% during trading on Friday, reaching $140.29. The company had a trading volume of 1,267,865 shares. The firm’s 50 day moving average price is $139.14 and its 200 day moving average price is $124.77. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market capitalization of $31.31 billion, a PE ratio of 60.84 and a beta of 1.40.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.13 EPS. Equities research analysts forecast that Alexion Pharmaceuticals will post $5.60 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-given-average-rating-of-buy-by-analysts/1601793.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.